Polymorphism of benzylthiouracil, an active pharmaceutical ingredient against hyperthyroidism
Visualitza/Obre
10.1016/j.ijpharm.2021.120378
Inclou dades d'ús des de 2022
Cita com:
hdl:2117/352783
Tipus de documentArticle
Data publicació2021-04-01
Condicions d'accésAccés obert
Llevat que s'hi indiqui el contrari, els
continguts d'aquesta obra estan subjectes a la llicència de Creative Commons
:
Reconeixement-NoComercial-SenseObraDerivada 3.0 Espanya
Abstract
The crystal structures of dimorphic benzylthiouracil, a drug against hyperthyroidism, have been redetermined and the atom coordinates of the two independent molecules of form I have been obtained for the first time. The dimorphism convincingly demonstrates the conformational versatility of the benzylthiouracil molecule. It has been established through calorimetric studies that the low-temperature form II transforms endothermically (¿II¿IH = 5.6(1.5) J g-1) into form I at 405.4(1.0) K. The high-temperature form I melts at 496.8(1.0) K (¿I¿LH = 152.6(4.0) J g-1). Crystallographic and thermal expansion studies show that form II is denser than form I, leading to the conclusion that the slope of the II-I equilibrium curve in the pressure-temperature phase diagram is positive. It follows that this dimorphism corresponds to a case of overall enantiotropic behaviour, which implies that both solid phases possess their own stable phase region irrespective of the pressure. Moreover, form II is clearly the stable polymorph under ambient conditions.
CitacióRietveld, I. [et al.]. Polymorphism of benzylthiouracil, an active pharmaceutical ingredient against hyperthyroidism. "International journal of pharmaceutics", 1 Abril 2021, vol. 598, p. 120378:1-120378:7.
ISSN0378-5173
Versió de l'editorhttps://www.sciencedirect.com/science/article/abs/pii/S0378517321001824
Col·leccions
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
BUT-IJP-2021-DracPreprint.pdf | 1,002Mb | Visualitza/Obre |